New Data From Helios-B Phase 3 Study Demonstrate Lower Rates Of Gastrointestinal Events In ATTR-CM Patients Treated With Vutrisiran
View all comments(0)
Sept 29 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:
NEW DATA FROM HELIOS-B PHASE 3 STUDY DEMONSTRATE LOWER RATES OF GASTROINTESTINAL EVENTS IN ATTR-CM PATIENTS TREATED WITH VUTRISIRAN
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.